Triiodothyronine, diluted according homeopathic techniques, modifies the programmed cell death of tadpole tail's explants

High Dilution is a solution beyond the Avogadro limits that, in the dependence of the applied succussion elicits a suppressive or a stimulant effect on a living cell, with a consequent generation of an oscillatory dose-effect curve. According to Bonamin et al. [1], “Perhaps, the most enigmatic feature regarding the properties of high dilutions is the non-linearity of their effects. In several studies employing in vivo and ex vivo models, especially involving iso-endopathy, an oscillatory potency-effect curve has appeared. The first observations were initially considered as artifacts, but the repetition of this pattern in different studies involving completely different experimental models, in times and places equally different, points out to the existence of a property intrinsic to dynamized systems.” ...

A Behavioural Analysis of Serotonergic Functional Status Following MDMA Exposure

<p>Rationale +/- 3,4-Methylenedioxymethamphetamine (MDMA) produces effects on a number of neurochemical systems. Many studies have shown that repeated MDMA administration produces deficits in central serotonergic neurotransmission, which have been suggested to underlie some of the behavioural changes associated with use. Objectives The present studies sought to evaluate the functional statuses of the serotonin transporter (SERT) and the serotonin2c (5-HT2c) and serotonin2a (5-HT2a) receptors following treatment with MDMA to determine whether behavioural deficits could be attributed to alterations in these proteins. Methods Rats received a pretreatment regimen of MDMA (4 x 10mg/kg MDMA injections administered at 2h intervals) or the saline vehicle and, 2 weeks later, [3H] paroxetine binding was undertaken to assess densities of SERT. In other groups, dose-effect curves for MDMA-produced hyperactivity were determined. Additional groups were tested following a 12-week withdrawal period from MDMA in order to assess whether there was recovery of function. The functional status of the SERT was further examined by determining the effect of MDMA pretreatment on the reduction in MDMA-produced hyperactivity (0.0 - 10.0mg/kg) produced by the selective serotonin reuptake inhibitor, clomipramine (0.0 - 5.0mg/kg). The ability for the 5-HT2c receptor agonist, m-CPP (0.0 - 2.5mg/kg) to produce hypolocomotion or increased emergence latency or for the 5-HT2a receptor agonist, DOI (0.0 - 2.0mg/kg) to produce wetdog shakes (WDS) were examined in MDMA pretreated rats. The ability for the 5-HT2c receptors to modulate MDMA-produced hyperactivity was assessed by examining the effect of MDMA pretreatment on the potentiation of MDMA-produced hyperactivity produced by the selective antagonist, RS102221 (0.0 - 1.0mg/kg). Conversely, the modulatory abilities of the 5-HT2a receptors were assessed by examining the effect of MDMA pretreatment on the attenuation of MDMA-produced hyperactivity produced by the antagonist, ritanserin (0.0 - 10.0mg/kg). Results MDMA pretreatment produced widespread reductions in SERT binding densities 2 weeks following administration. Prior exposure to MDMA rendered rats tolerant to MDMA-produced hyperactivity when tested 2, but not 12, weeks following MDMA administration. Two weeks following MDMA pretreatment rats were also less responsive to the clomipramine-produced attenuation of MDMA-produced hyperactivity. MDMA pretreatment failed to alter M-CPP -produced hypolocomotion or increased emergence latency, but decreased the ability for DOI to induce WDS. Further, MDMA pretreated rats exhibited tolerance to RS102221 as shown by a rightward shift in the dose effect curve and complete tolerance to ritanserin. Conclusions Following MDMA pretreatment, the decreased SERT binding densities and inability of clomipramine to attenuate MDMA-produced effects might explain tolerance to the locomotor activating effects produced by MDMA. Functional recovery also occurred with extended abstinence from the drug, suggesting that MDMA produced transient serotonergic alterations. The results support the idea that the 5-HT2a and 5-HT2c receptors that modulate MDMA-produced hyperactivity are functionally distinct from the receptors that mediate m-CPP- and DOI-induced behavioural responses, as m-CPP-produced behaviours were resilient, yet RS102221-induced effects were reduced, by MDMA pretreatment. RS102221 is highly selective in comparison to ritanserin, yet there was only one dose that produced significant potentiation of MDMA-produced hyperactivity, whereas there were several effective ritanserin doses. This suggests that the 5-HT2a receptors had a greater role in modulating MDMA-produced hyperactivity. Additionally, 5-HT2a receptors might be more susceptible to MDMA-induced desensitisation than 5-HT2c receptors, as MDMA pretreated rats exhibited some tolerance to the potentiating effects of RS102221 but were unresponsive to any ritanserin dose. In conclusion, MDMA-induced locomotor tolerance was attributable to decreased SERT densities and function as well as desensitisation of 5-HT2a receptors that facilitate hyperactivity.</p>

Factors Underlying +/- 3, 4-Methylenedioxymethamphetamine Self Administration

<p>Rationale: +/- 3, 4-Methylenedioxymethamphetamine (MDMA; Ecstasy) consumption has increased globally over the past two decades. Human studies have demonstrated that in a small proportion of users MDMA consumption may become problematic. Limited preclinical studies have evaluated the abuse potential of MDMA. Objectives: The present study sought to determine if MDMA selfadministration has similar addictive properties as other abused substances. Initial experiments sought to determine if MDMA could function as a reinforcer. Subsequent experiments assessed whether dopamine played a role in MDMA self-administration, whether MDMA self-administration was maintained by the presentation of a conditioned stimulus, and if extinguished MDMA self-administration could be reinstated. Methods: Animals were surgically implanted with indwelling intravenous catheters that allowed delivery of MDMA solution upon depression of an active lever. MDMA self-administration was examined in drug naïve and cocaine-trained animals. Further assessment of the reliability of self-administration was assessed using a yoked procedure, dose effect curves were obtained, vehicle substitution occurred, and progressive ratio procedures were used. The underlying role of dopamine in mediating MDMA self-administration was determined using the D1- like antagonist, SCH23390, and D2-like antagonist, eticlopride. Manipulation of the light and/or drug stimulus was used to provide initial assessment of the conditioning properties of MDMA. The ability of 10 mg/kg MDMA to reinstate responding previously maintained by MDMA was also determined. Results: MDMA was reliably self-administered in drug naïve and cocaine trained animals. Responding was selective to contingent MDMA administration, reduced with vehicle substitution, sensitive to dose manipulation, and increasing demand. A rightward shift in the dose effect curve was demonstrated after administration of SCH23390. Removal of both the light and drug stimuli produced a rapid reduction in responding. Removal of either the light or drug stimulus produced a gradual reduction over 15 days. Administration of MDMA reinstated responding previously maintained by MDMA. Conclusion: The demonstration of reliable MDMA self-administration provided a baseline for assessing MDMA abuse potential. MDMA selfadministration was mediated by dopaminergic mechanisms which may be similar to those demonstrated for other abused substances. MDMA selfadministration also produced conditioning - a feature of compulsive drug use. Responding previously maintained by MDMA was later reinstated by MDMA, demonstrating that MDMA use may result in relapse. MDMA has similar behavioural properties as other commonly abused substances.</p>

A Behavioural Analysis of Serotonergic Functional Status Following MDMA Exposure

<p>Rationale +/- 3,4-Methylenedioxymethamphetamine (MDMA) produces effects on a number of neurochemical systems. Many studies have shown that repeated MDMA administration produces deficits in central serotonergic neurotransmission, which have been suggested to underlie some of the behavioural changes associated with use. Objectives The present studies sought to evaluate the functional statuses of the serotonin transporter (SERT) and the serotonin2c (5-HT2c) and serotonin2a (5-HT2a) receptors following treatment with MDMA to determine whether behavioural deficits could be attributed to alterations in these proteins. Methods Rats received a pretreatment regimen of MDMA (4 x 10mg/kg MDMA injections administered at 2h intervals) or the saline vehicle and, 2 weeks later, [3H] paroxetine binding was undertaken to assess densities of SERT. In other groups, dose-effect curves for MDMA-produced hyperactivity were determined. Additional groups were tested following a 12-week withdrawal period from MDMA in order to assess whether there was recovery of function. The functional status of the SERT was further examined by determining the effect of MDMA pretreatment on the reduction in MDMA-produced hyperactivity (0.0 - 10.0mg/kg) produced by the selective serotonin reuptake inhibitor, clomipramine (0.0 - 5.0mg/kg). The ability for the 5-HT2c receptor agonist, m-CPP (0.0 - 2.5mg/kg) to produce hypolocomotion or increased emergence latency or for the 5-HT2a receptor agonist, DOI (0.0 - 2.0mg/kg) to produce wetdog shakes (WDS) were examined in MDMA pretreated rats. The ability for the 5-HT2c receptors to modulate MDMA-produced hyperactivity was assessed by examining the effect of MDMA pretreatment on the potentiation of MDMA-produced hyperactivity produced by the selective antagonist, RS102221 (0.0 - 1.0mg/kg). Conversely, the modulatory abilities of the 5-HT2a receptors were assessed by examining the effect of MDMA pretreatment on the attenuation of MDMA-produced hyperactivity produced by the antagonist, ritanserin (0.0 - 10.0mg/kg). Results MDMA pretreatment produced widespread reductions in SERT binding densities 2 weeks following administration. Prior exposure to MDMA rendered rats tolerant to MDMA-produced hyperactivity when tested 2, but not 12, weeks following MDMA administration. Two weeks following MDMA pretreatment rats were also less responsive to the clomipramine-produced attenuation of MDMA-produced hyperactivity. MDMA pretreatment failed to alter M-CPP -produced hypolocomotion or increased emergence latency, but decreased the ability for DOI to induce WDS. Further, MDMA pretreated rats exhibited tolerance to RS102221 as shown by a rightward shift in the dose effect curve and complete tolerance to ritanserin. Conclusions Following MDMA pretreatment, the decreased SERT binding densities and inability of clomipramine to attenuate MDMA-produced effects might explain tolerance to the locomotor activating effects produced by MDMA. Functional recovery also occurred with extended abstinence from the drug, suggesting that MDMA produced transient serotonergic alterations. The results support the idea that the 5-HT2a and 5-HT2c receptors that modulate MDMA-produced hyperactivity are functionally distinct from the receptors that mediate m-CPP- and DOI-induced behavioural responses, as m-CPP-produced behaviours were resilient, yet RS102221-induced effects were reduced, by MDMA pretreatment. RS102221 is highly selective in comparison to ritanserin, yet there was only one dose that produced significant potentiation of MDMA-produced hyperactivity, whereas there were several effective ritanserin doses. This suggests that the 5-HT2a receptors had a greater role in modulating MDMA-produced hyperactivity. Additionally, 5-HT2a receptors might be more susceptible to MDMA-induced desensitisation than 5-HT2c receptors, as MDMA pretreated rats exhibited some tolerance to the potentiating effects of RS102221 but were unresponsive to any ritanserin dose. In conclusion, MDMA-induced locomotor tolerance was attributable to decreased SERT densities and function as well as desensitisation of 5-HT2a receptors that facilitate hyperactivity.</p>

Factors Underlying +/- 3, 4-Methylenedioxymethamphetamine Self Administration

<p>Rationale: +/- 3, 4-Methylenedioxymethamphetamine (MDMA; Ecstasy) consumption has increased globally over the past two decades. Human studies have demonstrated that in a small proportion of users MDMA consumption may become problematic. Limited preclinical studies have evaluated the abuse potential of MDMA. Objectives: The present study sought to determine if MDMA selfadministration has similar addictive properties as other abused substances. Initial experiments sought to determine if MDMA could function as a reinforcer. Subsequent experiments assessed whether dopamine played a role in MDMA self-administration, whether MDMA self-administration was maintained by the presentation of a conditioned stimulus, and if extinguished MDMA self-administration could be reinstated. Methods: Animals were surgically implanted with indwelling intravenous catheters that allowed delivery of MDMA solution upon depression of an active lever. MDMA self-administration was examined in drug naïve and cocaine-trained animals. Further assessment of the reliability of self-administration was assessed using a yoked procedure, dose effect curves were obtained, vehicle substitution occurred, and progressive ratio procedures were used. The underlying role of dopamine in mediating MDMA self-administration was determined using the D1- like antagonist, SCH23390, and D2-like antagonist, eticlopride. Manipulation of the light and/or drug stimulus was used to provide initial assessment of the conditioning properties of MDMA. The ability of 10 mg/kg MDMA to reinstate responding previously maintained by MDMA was also determined. Results: MDMA was reliably self-administered in drug naïve and cocaine trained animals. Responding was selective to contingent MDMA administration, reduced with vehicle substitution, sensitive to dose manipulation, and increasing demand. A rightward shift in the dose effect curve was demonstrated after administration of SCH23390. Removal of both the light and drug stimuli produced a rapid reduction in responding. Removal of either the light or drug stimulus produced a gradual reduction over 15 days. Administration of MDMA reinstated responding previously maintained by MDMA. Conclusion: The demonstration of reliable MDMA self-administration provided a baseline for assessing MDMA abuse potential. MDMA selfadministration was mediated by dopaminergic mechanisms which may be similar to those demonstrated for other abused substances. MDMA selfadministration also produced conditioning - a feature of compulsive drug use. Responding previously maintained by MDMA was later reinstated by MDMA, demonstrating that MDMA use may result in relapse. MDMA has similar behavioural properties as other commonly abused substances.</p>

P02.02 Modeling of response to irradiation in recurrence glioblastoma’s cells culture

BACKGROUND Radiosensitivity of glioblastoma (GB) cells of local relapses may be markedly different from the primary tumor. Optimal doses and regimes of re-irradiation GB recurrence is not determined yet. MATERIAL AND METHODS GO1 primary GB cell culture was obtained during removal of a recurrent tumor after combined treatment, including irradiation of the surgical bed. Сell’s culture was irradiated by photon beams with energy 6 MeV and dose rate 600 MU/min. Irradiation performed in 1, 3 and 5 fractions, by 10 different doses for each regime. The dose range was determined experimentally for one fraction (5–250 Gy); for other regimes it was calculated according to the biological equivalent dose conception (3 fractions: 5–450 Gy, 5 fractions: 5–550 Gy). The proliferative activity of cells was investigate by MTT test. The results were normalized to the control. Dose-effect curves were plotted for each irradiation regime.The experimental data were approximated by calculated curves obtained by selecting the optimal parameters of the LQ-model and it’s modification. RESULTS Irradiation of GO1 by 1 fraction with the dose 5–250 Gy, causes a slow decrease in proliferative activity, which reaches a minimum value of 23% at 150 Gy and then remains constant. After irradiation by 3 fractions, proliferative activity of the GO1 gradually decrease only at a total dose over 120 Gy and reaches 37% after 450 Gy. When GO1 was irradiated in 5 fractions, a similar dose-effect curve was obtained, gradual decrease was observed to a value of 52% in the range of 250–500 Gy. Thus, the experimental dose-effect curves for irradiation of recurrence GB cells for 3 and 5 fractions have the appreciable “shoulder”, which could be explained by increased radioresistance. When approximating the experimental data by fitting the parameters of the LQ-model, the use of α/β = 8 provided the slope of the curve, close to the experimental data. For reflecting the “shoulder” an additional summand was introduced into the mathematical expression for the number of proliferating cells - a 105 Gy for 3 fractions and 255 Gy for 5 fractions. CONCLUSION Modified LQ-model could be used for an adequate mathematical description of the effectiveness of fractionated irradiation in relapsed GB culture cells in vitro. It’s necessary to introduce a summand into the formula that determines the formation of a “shoulder” on the dose-effect curve for this. The research was supported financially by RFBR (Project No. 18-29-01061).

Naratriptan is as effective as sumatriptan for the treatment of migraine attacks when used properly. A mini-review

Background Naratriptan, marketed in a low oral dose of 2.5 mg, is generally regarded as a less-effective triptan with a slower onset of action than most other triptans in the treatment of migraine attacks. In this review, naratriptan will be compared with sumatriptan, the standard triptan. Methods Papers on pharmacodynamics and pharmacokinetics and results from comparative clinical trials with oral and subcutaneous naratriptan versus other triptans were retrieved from PubMed. Results Naratriptan and sumatriptan have similar effects in relevant animal models. In a randomized controlled trial, oral naratriptan 2.5 mg is less effective than oral sumatriptan 100 mg after both 2 h and 4 h. In contrast, oral naratriptan 10 mg has a similar time-effect curve as oral sumatriptan 100 mg, in both its steepness and the efficacy at 2 h and 4 h. Subcutaneous naratriptan 10 mg (88% pain free at 2 h) was in one trial superior to subcutaneous sumatriptan 6 mg (55% pain free at 2 h). Conclusion Naratriptan was marketed for the treatment of migraine attacks as the “gentle triptan” in a low oral dose of 2.5 mg, a dose with no more adverse events than placebo. This low dose results in the slow onset of action and low efficacy of oral naratriptan, but in high doses oral naratriptan is similar to oral sumatriptan. Based on one randomized controlled trial, subcutaneous naratriptan has probably the greatest effect of any triptan.

Simple rules for resolved level-crossing spectra in magnetic field effects on reaction yields

In this work we derive conditions under which a level-crossing line in a magnetic field effect curve for a recombining radical pair will be equivalent to the electron spin resonance (ESR) spectrum and discuss three simple rules for qualitative prediction of the level-crossing spectra.

Simple rules for resolved level crossing spectra in magnetic field effects on reaction yields

In this work we derive conditions under which a level crossing line in magnetic field effect curve for a recombining radical pair will be equivalent to ESR spectrum, and discuss three simple rules for qualitative prediction of the level crossing spectra.